More Company News

HUTCHMED

Licensing agreement with GSK for KRAS-EGFR ATTC
03 Sep 2026Read More

HUTCHMED

Positive top line SANOVO Phase III data
31 Aug 2026Read More

HUTCHMED

China approval for Atled (fanregratinib) for FGFR2-Fusion/Rearrangement IHCC
28 Aug 2026Read More

HUTCHMED

Positive top line SAFFRON Phase III data
17 Aug 2026Read More

HUTCHMED

H126 interim results
30 Jul 2026Read More

HUTCHMED

NMPA approval for Orpathys in METamp gastric cancer
02 Jul 2026Read More

HUTCHMED

Pivotal Phase II fanregratinib data in IHCC at ESMO GI 2026
25 Jun 2026Read More

HUTCHMED

Sovleplenib ESLIM-02 Phase III data in wAIHA at EHA 2026 Congress
12 Jun 2026Read More

HUTCHMED

Clinical data to be presented at the 2026 ASCO Annual Meeting
22 May 2026Read More

HUTCHMED

China NMPA Approval for fruquintinib + sintilimab combination in RCC
21 May 2026Read More

1 2 3 4 … 24
Return to HUTCHMED
© 2019-2026 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).